SEC Form 4 · accession 0001179110-15-015767
Assertio Therapeutics, Inc · ASRT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
August J Moretti
Officer — Chief Financial Officer & SVP
Period of report
Dec 1, 2015
Accepted (ET)
Dec 3, 2015 · 6:32 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001005201
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF1,F2 | Dec 1, 2015 | F | 7,329 | $19.00 | D | 36,319 | D | |
| Common StockF3,F5,F4 | Dec 3, 2015 | S | 13,159 | $18.12 | D | 23,160 | D | |
| Common StockF6,F3,F4 | Dec 3, 2015 | S | 1,841 | $18.01 | D | 21,319 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares of restricted stock forfeited to meet the tax liability triggered by the vesting of such restricted stock.
- F2Amount does not include any unvested restricted stock previously reported on Form 4 by the reporting person.
- F3The sales reported in this Form 4 were sold pursuant to a rule 10b5-1 trading plan adopted by the reporting person.
- F4The price reported is a weighted average price. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares at each price within the range set forth in this footnote.
- F5The Common stock sold was acquired as part of a Restricted Stock Units (RSUs) award of 28,500 units granted on February 7, 2013. The RSUs vest over four years on December 1 of each year.
- F6These shares form part of 1,867 shares acquired under the Company's ESPP and were purchased at $4.90 per share.